Table 2.

Summary of AEs in the study period

	Research (gap schedule) (n = 282)	Control (n = 269)
Any AEs	282 (100%)	268 (99.6%)
AE grade ≥3	181 (64.2%)	158 (58.7%)
Any SAE	96 (34.0%)	93 (34.6%)
SAE related to carboplatin	60 (21.3%)	49 (18.2%)
SAE related to paclitaxel	63 (22.3%)	47 (17.5%)
SAE related to olaparib	45 (16.0%)	−
Missed doses due to toxicity	114 (40.4%)	76 (28.3%)
Modified doses due to toxicity	109 (38.7%)	48 (17.8%)
Treatment discontinued because of toxicity	21 (7.4%)	22 (8.2%)
Red cell transfusion required during chemotherapy	145 (51.4%)	82 (30.5%)